Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05057806 · ClinicalTrials.gov registry record · Early Phase 1
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
A Early Phase 1 study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05057806: Recruiting Early Phase 1 study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05057806 is a Early Phase 1 study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 30 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05057806, a Early Phase 1 study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Primary Outcome
A measure of phosphocreatine change from baseline to study end
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 25 MG
Study Locations (2)
Texas
- Texas Diabetes Institute - University Health System - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
What NCT05057806 shows while recruiting
NCT05057806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05057806 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05057806 about?
NCT05057806 is a clinical study titled "SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan". The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
What is the current status of trial NCT05057806?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2021-01-13. Estimated completion is 2027-03-31.
What conditions does trial NCT05057806 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT05057806?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 25 MG (DRUG).
Who is sponsoring clinical trial NCT05057806?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05057806 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05057806's enrollment target sits among peer trials
30 256th of 327 higher than 57 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
SGLT2i, Hepatic Glucose Production, and SNS
RECRUITING · Early Phase 1
-
Precision Dosing of Metformin in Youth With T2D
RECRUITING · Early Phase 1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Type 2 Diabetes and Blood Brain Barrier Improvement
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI